Company intelligence / Profile preview

Silverback Capital

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Lead candidate SBT6050 (anti-HER2 antibody conjugated to TLR8 agonist) demonstrated potent activation of myeloid cells in preclinical studies with durable, curative single-agent activity in HER2-expressing tumors. Clinical investigation expected to begin in 2020.

Therapeutic areas: OncologyImmunologyRheumatologyInfectious Diseases
Modalities: Antibody-drug conjugateMonoclonal antibody
Industry: Biotech

Partnerships

AstraZeneca (co-development of immunotherapy)Takeda Pharmaceuticals (drug delivery expertise)Pfizer (oncology applications)Merck (combination therapies)National Cancer Institute (research funding)AbbVie (collaboration valued up to $1.2 billion)Genentech (collaboration valued at $1.9 billion)

Beyond the preview

Go deeper on Silverback Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silverback Capital.

Explore the full profile